Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo’s Support on Rett Syndrome Program Progress

Company Overview - Taysha Gene Therapies, Inc. (TSHA) is a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system, including Rett syndrome [3]. Investment Potential - TSHA is ranked sixth in a list of the 20 Best Biotech Stocks Under $20, indicating strong investment potential [1]. - Wells Fargo has raised its price target on TSHA from $8 to $11, maintaining an Overweight rating, citing anticipated outperformance in 2026 due to advancements in its Rett syndrome research [1][2]. Program Progress - TSHA reported progress on its TSHA-102 Rett syndrome program, with the first patient in the REVEAL pivotal phase dosed in Q4 2025 [2]. - The FDA has authorized the use of ASPIRE trial data in the proposed Biologics License Application (BLA), with updated safety and efficacy data from REVEAL Part A expected in H1 2026 [2]. - TSHA plans to complete dosing in both the REVEAL and ASPIRE studies by Q2 2026 [2].